Accessible Unlicensed Requires Authentication Published by De Gruyter April 7, 2006

Hepatorenal syndrome

Selda Demırtaş, Murat Can and Ayşegül Yarpuzlu

Abstract

This article summarizes the literature on current definition, suggested pathogenetic mechanisms and the role of laboratory assessment in the differential diagnosis of hepatorenal syndrome (HRS) from other causes of renal disease that may arise during hepatic cirrhosis and some diseases affecting both liver and kidney. It should be remembered that the main theory suggested for the pathogenesis of HRS is the arterial vasodilation hypothesis of portal hypertension, ending in type 1 and type 2 HRS, but there is no consensus supporting either mechanism as a solid theory for initiation of HRS pathogenesis to date. No laboratory test can firmly establish a diagnosis of HRS, which is mainly based on the absence of any specific cause of renal failure. Laboratory and ultrasonographic tests based on non-invasive techniques are being investigated as possible diagnostic approaches.


Corresponding author: Murat Can, Karaelmas University, Faculty of Medicine, Department of Biochemistry, Zonguldak, Turkey Phone: +90-372-2610169, Fax: +90-372-2610155

References

1. Dagher L, Moore K. The hepatorenal syndrome. Gut 2001; 49:729–37.Search in Google Scholar

2. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164–76.Search in Google Scholar

3. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105:229–36.Search in Google Scholar

4. Badalamenti S, Graziani G, Salerno F, Ponticello C. Hepatorenal syndrome: new perspectives in pathogenesis and treatment. Arch Intern Med 1993; 153:1957–67.Search in Google Scholar

5. Rhodes J, Bosch J, Arroyo V. Clinical types and drug therapy of renal impairment in cirrhosis. Postgrad Med J 1975; 51:492–7.Search in Google Scholar

6. Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997; 17:233–47.Search in Google Scholar

7. Watt K, Uhanova J, Minuk GY. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center. Am J Gastroenterol 2002; 97:2046–50.Search in Google Scholar

8. Bilotta J, Pazik M, Greizersen H, Acara M. Renal effect of ethanol in isolated perfused rat kidney. Eur J Pharmacol 1984; 98:109–12.Search in Google Scholar

9. Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77:215–22.Search in Google Scholar

10. Epstein M. Renal prostaglandins and the control of renal function in liver disease. Am J Med 1986; 80:46–55.Search in Google Scholar

11. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8:1151–7.Search in Google Scholar

12. Arroyo V, Guevera M, Gines P. Hepatorenal syndrome: pathogenesis and treatment. Gastroenterology 2002; 122:1658–76.Search in Google Scholar

13. Colombato L, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1991; 15:323–8.Search in Google Scholar

14. Gines P, Martin PY, Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int 1997; 51(Suppl):S77–82.Search in Google Scholar

15. Lang F, Tschernko E, Schulze E, Ottl I, Ritter M, Volkl H, et al. Hepatorenal reflex regulating kidney function. Hepatology 1991; 14:590–4.Search in Google Scholar

16. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide. Lancet 1991; 337:776–8.Search in Google Scholar

17. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balazo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139–41.Search in Google Scholar

18. Sogni P, Garnier P, Gadano A, Moreau R, Dall'Ava Santucci J, Dinh-Xuan AT, et al. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol 1995; 23:471–3.Search in Google Scholar

19. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl Med 1991; 329:2002–12.Search in Google Scholar

20. Pizcueta MP, Pique JM, Fernandez M, Bosch J, Rodes J, Whittle BJ, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103:1909–15.Search in Google Scholar

21. Forrest EH, Jones AL, Dillon JF, Walker J, Hayes PC. The effect of nitric oxide synthase inhibition on portal pressure and azygos blood in patients with cirrhosis. J Hepatol 1995; 23:254–8.Search in Google Scholar

22. Hu LF, Sealey JE, Chen R, Zhou Y, Merali C, Shi YX, et al. Nitric oxide synthase inhibition accelerates the pressor response to low-dose angiotensin II, exacerbates target organ damage, and induces renin escape. Am J Hypertens 2004; 17:395–403.Search in Google Scholar

23. Garcia-Estan J, Atucha NM, Sabio JM, Vargas F, Quesda T, Romero JC. Increased endothelium-dependent renal vasodilation in cirrhotic rats. Am J Physiol 1994; 267:549–53.Search in Google Scholar

24. Moore K, Ward P, Taylor G, Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991; 100:1069–77.Search in Google Scholar

25. Guarner C, Colina I, Guarner F, Corzo J, Prieto J, Vilardell F. Renal prostaglandins in cirrhosis of the liver. Clin Sci 1986; 70:477–84.Search in Google Scholar

26. Laffi G, La Villa G, Pinzani M, Ciabattoni G, Patrignani P, Mannelli M, et al. Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology 1986; 90:274–82.Search in Google Scholar

27. Rimola A, Gines P, Arroyo V, Camps J, Perez Ayuso RM, Quintero E, et al. Urinary excretion of 6-ketoprostaglandin F1-alpha, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites: relationship to functional renal failure(hepatorenal syndrome). J Hepatol 1986; 3:111–7.Search in Google Scholar

28. Claria J, Kent JD, Lopez-Parra M, Escolar G, Ruiz-del-Arbol L, Gines P, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41:579–87.Search in Google Scholar

29. Guevera M, Gines P, Jimenez W, Sort P, Fernandez Esparrach G, Escorsell A, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114:336–43.Search in Google Scholar

30. Fernandez-Rodriguez CM, Prada IR, Prieto J, Montuenga LM, Elssasser T, Quiroga J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol 1998; 29:250–6.Search in Google Scholar

31. Henriksen JH, Ring-Larsen H, Kanstrup IL, Fradsen E, Bendtsen F. Circulating norepinephrine and central hemodynamics in patients with cirrhosis. Scand J Gastroenterol 1985; 20:1185–90.Search in Google Scholar

32. Bichet DG, Van Putten VJ, Schrier RW. Potential role of increased sympathetic activity in impaired sodium and water excretion in cirrhosis. N Engl J Med 1982; 307:1552–7.Search in Google Scholar

33. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482–7.Search in Google Scholar

34. Solis-Herruzo JA, Duran A, Favelza V, Castellano G, Madrid JL, Munoz-Yague MT, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepatorenal syndrome. J Hepatol 1987; 5:167–73.Search in Google Scholar

35. Wong F, Blendis L. New challenge of hepatorenal syndrome: prevention and treatment. Hepatology 2001; 34:1242–51.Search in Google Scholar

36. Moreau R. Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 2002; 17:739–47.Search in Google Scholar

37. Moller S, Emmeluth C, Henricksen JH. Elevated circulating plasma endothelin-1 concentrations in cirrhosis. J Hepatol 1993; 19:285–90.Search in Google Scholar

38. Uchihare M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 1992; 16:95–9.Search in Google Scholar

39. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med 1992; 327:1774–8.Search in Google Scholar

40. Soper CP, Latif AB, Bending MR. Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet 1996; 347:1842–3.Search in Google Scholar

41. Kitamura H, Shimada R, Kobayashi A, Nomura K, Noike T, Harada H, et al. Plasma concentration of endothelin-1 does not reflect renal vasoconstriction as estimated by duplex ultrasonography in cirrhosis. Dig Dis Sci 1997; 42:542–5.Search in Google Scholar

42. Morrow JD, Moore KP, Award JA, Ravenscraft MD, Marini G, Badr K, et al. Marked overproduction of non-cyclo-oxygenase derived prostanoids (F2-isoprostane) in the hepatorenal syndrome. J Lipid Mediators 1993; 6:417–20.Search in Google Scholar

43. Holt S, Marley R, Goodier D, Harry D, Fernando B, Moore K. Oxidant stress and renal dysfunction in cholestasis. Gut 1998; 43:153.Search in Google Scholar

44. Holt S, Marley R, Fernando B, Harry D, Anand R, Goodier D, et al. Acute cholestasis-induced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney Int 1999; 55:271–7.Search in Google Scholar

45. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:1637–48.Search in Google Scholar

46. Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of the neutrophil chemotaxin, interleukin 8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. Hepatology 1993; 18:41–6.Search in Google Scholar

47. Sheron N, Bird G, Goka J, Alexander G, Williams R. Elevated plasma interleukin 6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991; 84:449–53.Search in Google Scholar

48. Fernando B, Marley R, Holt S, Anand R, Harry D, Sanderson P, et al. Acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. Hepatology 1998; 28:689–94.Search in Google Scholar

49. Lopez-Talavera JC, Levitzki A, Martinez M, Gazit A, Esteban R, Guardia J. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases NO production in cirrhotic rats with portal hypertension and ascites. J Clin Invest 1997; 100:664–70.Search in Google Scholar

50. Lopez-Talavera JC, Merrill WW, Groszman RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal hypertensive rats. Gastroenterology 1995; 108:761–7.Search in Google Scholar

51. Wilkinson SP, Willams R. Renin-angiotensin-aldosterone system in cirrhosis. Gut 1980; 21:545–54.Search in Google Scholar

52. Schroeder ET, Eich RH, Smulyan H, Gould AB, Gabuzda GJ. Plasma renin level in hepatic cirrhosis: relation to functional renal failure. Am J Med 1970; 49:189–91.Search in Google Scholar

53. Cobden I, Shore A, Wilkinson R, Record CO. Captopril in the hepatorenal syndrome. J Clin Gastroenterol 1985; 7:354–60.Search in Google Scholar

54. Schroeder ET, Anderson GH. Effect of blockade of angiotensin II on blood pressure, renin and aldosterone in cirrhosis. Kidney Int 1976; 9:511–9.Search in Google Scholar

55. Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early advanced cirrhosis. Gastroenterology 2000; 118:565–72.Search in Google Scholar

56. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29:334–9.Search in Google Scholar

57. Debarnardi-Venon D, Baretti C, Marzano A, Marzano A, Baronio M, Todros L, et al. Efficacy of irbesartan, an angiotensin II receptor selective antagonist, in the treatment of portal hypertension. Dig Dis Sci 2002; 47:401–4.Search in Google Scholar

58. Garcia-Tsao G. Angiotensin receptor antagonist in the pharmacological therapy: a caution. Gastroenterology 1999; 117:740–2.Search in Google Scholar

59. Claria J, Jimenez W, Arroyo V, La Villa G, Lopez C, Asbert M, et al. Effect of V1-vasopressin receptor blockade on arterial pressure in conscious rats with cirrhosis and ascites. Gastroenterology 1991; 100:494–501.Search in Google Scholar

60. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35–41.Search in Google Scholar

61. Rodriguez-Perez F, Groszmann RJ. Pharmacologic treatment of portal hypertension. Gastroenterol Clin North Am 1992; 21:15–40.Search in Google Scholar

62. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36:941–8.Search in Google Scholar

63. Podolsky DK, Isselbacher KJ. Cirrhosis. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, editors. Harrison's principles of internal medicine, 11th ed. New York: McGraw-Hill, 1987.Search in Google Scholar

64. Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994; 154:201–5.Search in Google Scholar

65. Linas SL, Schaefer JW, Moore EE, Good JT Jr, Giansiracusa R. Peritoneovenous shunt in the management of the hepatorenal syndrome. Kidney Int 1986; 30:736–40.Search in Google Scholar

66. Terra C, Guevara M, Torre A, Gilabert R, Fernandez J, Martin Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129:1944–53.Search in Google Scholar

67. Platt JF, Ellis JH, Rubin JM, Merion RM, Lucey MR. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20:362–9.Search in Google Scholar

68. Abuelo JG. Diagnosing vascular causes of renal failure. Ann Intern Med 1995; 123:601–14.Search in Google Scholar

69. Brady HR, Singer GG. Acute renal failure. Lancet 1998; 346:1533–40.Search in Google Scholar

70. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334:1448–60.Search in Google Scholar

71. Heyman SN, Darmon D, Goldfarb M, Bitz H, Shina A, Rosen S, et al. Endotoxin-induced renal failure. A role for altered renal microcirculation. Exp Nephrol 2000; 8:266–74.Search in Google Scholar

72. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 2003; 37:233–43.Search in Google Scholar

73. Klahr S, Miller SB. Acute oliguria. N Engl J Med 1998; 338:671–5.Search in Google Scholar

74. Porcel A, Diaz F, Rendon P, Marcias M. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162:323–8.Search in Google Scholar

75. Papadakis MA, Arieff A. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945–52.Search in Google Scholar

76. De Santo NG, Anastasio P, Loguercio C, Spitali L, Del Vecchio BC, Corvinelli M, et al. Creatinine clearance: an adequate marker of renal filtration in patients with early posthepatic cirrhosis (child A) without fluid retention and muscle wasting. Nephron 1995; 70:421–4.Search in Google Scholar

77. Woitas RP, Stoffel-Wagner B, Flommersfeld S, Poege U, Schiedermaier P, Klehr HU, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000; 46:712–5.Search in Google Scholar

78. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830–8.Search in Google Scholar

79. Herget-Rosenthal SH, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 2000; 20:97–102.Search in Google Scholar

80. Orlando R, Musap M, Plebani M, Piccoli P, De Martin S, Florenai M, et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 2002; 48:850–8.Search in Google Scholar

81. Newman DJ, Price CP. Renal function and nitrogen metabolites. In: Burtis CA, Ashwood ED, editors. Tietz textbook of clinical chemistry, 3rd ed. Philadelphia, PA: Saunders, 1999:1251–4.Search in Google Scholar

82. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992; 38:20–7.Search in Google Scholar

83. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function – a review. Clin Chem Lab Med 1999; 37:389–95.Search in Google Scholar

84. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 2000; 54:203–9.Search in Google Scholar

85. Kyhse-Andersen J, Schimidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, et al. Serum cystatin C, determined by a rapid automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40:1921–6.Search in Google Scholar

86. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Greubb AO, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47:312–8.Search in Google Scholar

87. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C: a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 1998; 101:875–81.Search in Google Scholar

88. Helin I, Axenram M, Grubb A. Serum cystatin C as a determinant of glomerular filtration rate in children. Clin Nephrol 1998; 49:221–5.Search in Google Scholar

89. Stickle D, Cole B, Haock K, Hruska KA, Scott MG. Correlation of plasma concentrations of cystatin C and creatinine to inulin clearance in a pediatric population. Clin Chem 1998; 44:1334–8.Search in Google Scholar

90. Burkhardt H, Bojarsky G, Gretz N, Gladish R. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimation of true glomerular filtration rate in the elderly. Gerontology 2002; 48:104–6.Search in Google Scholar

91. Burkhardt H, Bojarsky G, Gladish R. Diagnostic efficiency of cystatin C and serum creatinine as markers of reduced glomerular filtration rate in the elderly. Clin Chem Lab Med 2002; 40:1135–8.Search in Google Scholar

92. Gerbes AL, Gülberg V, Bizler M, Vogester M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50:106–10.Search in Google Scholar

93. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311:81–9.Search in Google Scholar

Received: 2005-7-7
Accepted: 2006-1-3
Published Online: 2006-4-7
Published in Print: 2006-4-1

©2006 by Walter de Gruyter Berlin New York